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A B S T R A C T
Aim of the study was to evaluate the diagnostic performance of the Rose Bengal score test for Sjøgren’s syndrome
(SS), and to explore differences between other tests and examinations. All participants were examined, including (but not
limited to) unstimulated (UWS) and stimulated (SWS) whole saliva, labial gland biopsy (LGB or focus score), oph-
thalmologic questionnaire (ocular surface disease index OSDI) and objective tests: Schirmer test 1 (Sch.1), Schirmer test
2 (Sch.2), Tear Break-up Time (TBUT) test and Rose Bengal score (RBS). Data were analyzed using Mann Whitney
U-test, Receiver Operating Characteristic analysis, with specificity and sensitivity calculations and Spearman’s corre-
lation test. ROC curves showed a poor diagnostic performance of TBUT and OSDI. Sch.1, Sch.2 and LGB all exhib-
ited a high diagnostic performance. RBS exhibited the best performance (sensitivity 100,00; specificity 100,00; AUC
1,000). Study reveals the scarce reliability of TBUT, OSDI and Sch.1, and emphasizes RBS as the test of choice in the
SS diagnosis.
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Introduction
Sjøgren’s syndrome (SS) is an autoimmune exocrino-
pathy of unknown etiology, prominently affecting the sal-
ivary and lacrimal glands1. Xerostomia and xerophthal-
mia are often the presenting symptoms of the disease.
It is characterized by progressive lymphocytic infil-
tration of exocrine glands and epithelia in multiple si-
tes2–4. The peak incidence is in the fourth and fifth de-
cades of life, with a female to male incidence ratio of 9:1.
The major diagnostic tool is the labial salivary gland bi-
opsy, which characteristically shows focal lymphocytic
infiltration5. It is also a painful procedure with small but
significant proportion of unreliable results6.
Systematic multidisciplinary approach is required in
proper evaluation of SS, including assessment of the oral,
ocular and systemic components of the disease. Numer-
ous criteria have been proposed to facilitate the diagnosis
of SS. The American-European Consensus Group crite-
ria4 proved to be the most practical, since they take into
consideration the multisystemic nature of the disease.
The set of criteria includes 6 different items and 4 of
them must be present in patients for the diagnosis of SS.
Two typical items are included in the majority of the
diagnostic sets, subjective symptoms and tests for eye
dryness, but little agreement on the cut off values is pres-
ent. The ocular surface is now considered as an inte-
grated unit7, and any dysfunction results in a scarce or
unstable preocular tear film and in the presence of un-
refreshed tears in which soluble mediators store up. A
range of criteria have been proposed for the evaluation of
patients with dry eye. The most frequently used tests are
Schirmer test 1 and Tear Break-up Time test8.
Regardless of the fact that many scientific evidence
suggest to also include other tests in the assessment of
dry eye9, in the practice it is still based upon a low Sch.1
and/or TBUT. The purpose of the present work was to de-
termine the diagnostic performance of Rose Bengal score
(RBS) test in differential diagnosis of SS vs. other non-
-Sjøgren’s »Sicca syndrome«.
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Materials and Methods
The study included 66 patients, examined during the
period April 2006–May 2008 and grouped as follows:
• Sjøgren’s syndrome (SS) patients (48 subjects), diag-
nosed according to the American-European Consensus
Group criteria4;
• Sicca syndrome (Sicca S) patients (18 subjects) report-
ing subjective symptoms of xerophthalmia and xero-
stomia, but who did not satisfy the classification crite-
ria for SS.
Group and sex distribution data are reported in Table 1.
Patients were asked to answer on 12 questions from a
validated questionnaire (ocular surface disease index
OSDI). Questions were associated to their subjective
symptoms felt the week before. The score of the ques-
tionnaire ranges from 0 to 12 (no disability), to 13–22
(light dry eye), to 23–32 (moderate dry eye), to 33–100
(severe dry eye)10.
The Schirmer test were performed as described else-
where9 by using sterile Schirmer strips without anesthe-
sia (Sch.1) or after application of tetracaine 0.5% (Sch.2),
in room controlled for lighting (dim light room), temper-
ature (20–22°C), and humidity (40–60%). Abnormal va-
lue was regarded as 10 mm/wetting after 5 min for
Sch.1 and 5 mm/wetting after 5 min for Sch.2.
The TBUT was performed as described elsewhere9
and the time of rupture <10 s was considered as abnormal.
Rose Bengal staining was performed as already re-
ported and scored11. Pathological vital staining was sco-
red as >9/18 in six areas measured.
Statistical analysis
Data were statistically evaluated by applying the Sta-
tistical Package for the Social Sciences (SPSS) for Win-
dows 11.0 for the independent sample t-test, the Mann-
-Whitney U-test for unpaired data, and the logistic regre-
ssion for selected groups of tests. For nonparametric data
the descriptive statistic applied were the analysis of me-
dian and 25–75 percentiles. P values less than 0.05 were
regarded as statistically significant.
The prevalence of the SS (the proportion of patients
who have the disease in the population under testing)
was calculated using the population included in our
study as a reference. Each of the test performed were
analysed for sensitivity (the percentage of symptomatic
patients who tested positive, a large sensitivity means
that a negative test can rule out the disease) and specific-
ity (the percentage of normal subjects who tested nega-
tive, a large specificity means that a positive test can con-
firm the disease)12. Specificity and sensitivity were calcu-
lated comparing SS patients vs. Sicca S patients. Data
were also processed in order to calculate receiver-operat-
ing characteristics (ROC) curves13. ROC curve expresses
the diagnostic exactness of test variables by plotting the
sensitivity of the test against the specificity at all possi-
ble thresholds.
We used the likelihood ratio, a measure that combines
information about the sensitivity and specificity, and of-
fers a direct valuation of how much a positive or negative
result changes the likelihood that a patient would have
the disease, to summarize the data about diagnostic
tests. The likelihood ratio for positive results (LR+; sen-
sitivity divided by 1-specificity) demonstrates how much
the odds of the disease increase when a test is positive.
Results
Table 2 summarizes the medium±SD of the values re-
sulted from the study, collected from each group of pa-
tients. Data shown in separate figures represents min-
-max values range (bounded with lines), results values
from 25% to 75% and median (black line) from each
group of patients.
Unstimulated whole saliva (UWS) is expressed in
mL/5 min. Mean values in SS patients were 0.33±0.42
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TABLE 1
NUMBER AND SEX DISTRIBUTION OF PATIENTS IN GROUPS
WITH SJØGREN'S SYNDROME (SS) AND SICCA SYNDROME
(SICCA S)
TOTAL PATIENTS NUMBER (N=66)
Male (N=6) Female (N=60)
SS (N=48) 6 42
Sicca S (N=18) 0 18
Total (N=66) 6 60
TABLE 2
SUMMARY OF THE RESULTS (X±SD) IN GROUP WITH SJØGREN'S SYNDROME (SS) AND SICCA SYNDROME (SICCA S) FOR EACH
PROVIDED TEST
Test Measure SS Sicca S p
Unstimulated whole saliva (UWS) mL/5min 0.33±0.42 0.65±0.21 <0.001
Stimulated whole saliva (SWS) mL/5 min 0.88±1.10 1.90±0.47 <0.001
Ocular surface disease index (OSDI) Score 52.66±22.02 34.75±11.77 <0.003
Schirmer test 1 (Sch.1) mm/5 min 13.81±14.30 29.17±12.70 <0.001
Schirmer test 2 (Sch.2) mm/5 min 4.72±5.66 17.17±11.06 <0.001
Tear Break-up Time (TBUT) test Seconds 8.69±6.39 13.00±6.36 <0.008
Rose Bengal score (RBS) Score 10.56±3.35 2.83±2.33 <0.001
mL/5 min and in Sicca S patients were 0.65±0.21 mL/5
min, with statistically significant differences (p<0.001)
between groups (Table 2).
Median value, results from 25%–75% and min-max
values range for UWS are presented in Figure 1.
Stimulated whole saliva (SWS) is expressed in mL/5
min. Medium values in SS patients were 0.88±1.10 mL/5
min and in Sicca S patients were 1.90±0.47 mL/5 min,
with statistically significant differences (p<0.001) be-
tween groups (Table 2).
Median value, results from 25%–75% and min-max
values range for SWS are presented in Figure 2.
Dry eye symptoms were reported by all patients (sco-
re of the subjective symptom questionnaire always >12),
ranging from moderate in Sicca S to severe in SS pa-
tients, with statistically significant differences (p<0.003)
between groups (Table 2).
Median value, results from 25%–75% and min-max
range values for OSDI are presented in Figure 3.
Mean values of pathological Schirmer test 1 (paper
wetting <10 mm/5 min) were not found in any group,
but with statistically significant differences (p<0.001)
between groups (Table 2).
Median value, results from 25%–75% and min-max va-
lues range for Schirmer test 1 are presented in Figure 4.
Mean values of Schirmer test 2 showed a pathological
decrease of tear production only in SS patients, with stati-
stically significant differences (p<0.001) between groups
(Table 2).
Median value, results from 25%–75% and min-max va-
lues range for Schirmer test 2 are presented in Figure 5.
Tear Break-up Time (TBUT) test showed pathological
mean values in SS group, with statistically significant
differences (p<0.008) between groups (Table 2). Median
value, results from 25%–75% and min-max values range
for TBUT are presented in Figure 6.





















Fig. 1. Median (black line), results from 25%–75% and range
min-max (bounded with lines) values for unstimulated whole sa-
liva (UWS) in groups of patients with Sjøgren’s syndrome (SS)





















Fig. 2. Median (black line), results from 25%–75% and range
min-max (bounded with lines) values for stimulated whole saliva
(SWS) in groups of patients with Sjøgren’s syndrome (SS) and






















Fig. 3. Median (black line), results from 25%–75% and range
min-max (bounded with lines) values for Ocular surface disease
index (OSDI) in groups of patients with Sjøgren’s syndrome (SS)














Fig. 4. Median (black line), results from 25%–75% and range min-
-max (bounded with lines) values for Schirmer test 1 (Sch.1) in
groups of patients with Sjøgren’s syndrome (SS) and sicca syn-
drome (Sicca S).
The Rose Bengal score resulted in the pathological
range only in the SS patients, with statistically signifi-
cant differences (p<0.001) when compared to Sicca S
group (Table 2).
Median value, results from 25%–75% and range min-
-max values for RBS are presented in Figure 7.
In our study, the Schirmer test 1 performed poorly as
a diagnostic test for SS patients (sensitivity 75.00, speci-
ficity 83.33) and ROC plot analysis (Figure 8) demon-
strates relatively flat curve, close to diagonal line (area
under the curve 0.781).
Schirmer test 2 showed higher sensitivity (100.00)
and slightly worse specificity value (66.67) in comparison
with Schirmer test 1 (Table 3), with area under the curve
0.802 (Figure 9).



















Fig. 5. Median (black line), results from 25%–75% and range min-
-max (bounded with lines) values for Schirmer test 2 (Sch.2) in












Fig. 6. Median (black line), results from 25%–75% and range min-
-max (bounded with lines) values for Tear Break-up Time
(TBUT) test in groups of patients with Sjøgren’s syndrome (SS)














Fig. 7. Median (black line), results from 25%–75% and range min-
-max (bounded with lines) values for Rose Bengal score (RBS) in
groups of patients with Sjøgren’s syndrome (SS) and sicca syn-
drome (Sicca S).
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Fig. 8. Receiver Operating Characteristic (ROC) curve for Schir-
mer test 1.
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Fig. 9. Receiver Operating Characteristic (ROC) curve for Schir-
mer test 2.
The TBUT also performed poorly as a diagnostic test
for SS with sensitivity 62.50 and specificity 83.33 (Table
3). ROC plot analysis also indicated rather low accuracy
of the test (area under the curve 0.714) (Figure 10).
The OSDI performed somewhat better than TBUT,
with sensitivity 56.25 and specificity 100.00 (Table 3).
ROC plot analyses demonstrated a curve slightly ap-
proaching the upper left corner of the diagram (Figure
11), displaying somewhat larger area under the curve
(0.740), (Table 4).
In the present study, the tests that showed the best
performance were Rose Bengal score with sensitivity
100.00 and specificity 100.00 (Table 3), area under the
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TABLE 3
CUT OFF VALUES AND COORDINATES OF RECEIVER
OPERATING CHARACTERISTIC CURVES WITH LIKELIHOOD
RATIO (LR) FOR POSITIVE (+) AND NEGATIVE (–) RESULTS FOR
EACH PROVIDED TEST
Test Cut off Sensitivity Specificity +LR –LR
OSDI >55.6 56.25 100.00 0.00 0.44
Sch.1 23 75.00 83.33 4.50 0.30
Sch.2 17 100.00 66.67 3.00 0.00
TBUT 7.5 62.50 83.33 3.75 0.45
Rose Bengal score >6 100.00 100.00 0.00 0.00
Focus score 1 56.25 100.00 0.00 0.44
TABLE 4
STATISTICAL VALUES REPORT WITH AREA UNDER THE
CURVE, STANDARD ERROR AND 95% CONFIDENCE INTERVAL








OSDI 0.740 0.0632 0.617–0.840
Sch.1 0.781 0.0698 0.662–0.874
Sch.2 0.802 0.0674 0.686–0.890
TBUT 0.714 0.0759 0.589–0.818
Rose Bengal score 1.000 0.000 0.945–1.000
Focus score 0.823 0.0646 0.709–0.906
100-Specificy














Fig. 10. Receiver Operating Characteristic (ROC) curve for Tear
Break-up Time (TBUT) test.
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Fig. 11. Receiver Operating Characteristic (ROC) curve for Ocu-
lar surface disease index (OSDI).
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Fig. 12. Receiver Operating Characteristic (ROC) curve for Rose
Bengal score (RBS).
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Fig. 13. Receiver Operating Characteristic (ROC) curve for focus
score.
curve in the ROC plot analyses being 1.000 (Table 4, Fig-
ure 12); and labial gland biopsy focus score with sensitiv-
ity 56.25 and specificity 100.00 (Table 3), area under the
curve in the ROC plot analysis being 0.823 (Table 4, Fig-
ure 13). The ROC curves of these tests showed the ten-
dency to approach the upper left corner of the diagram,
especially the curve related to Rose Bengal score, indicat-
ing the highest diagnostic performance.
Discussion
Dry eyes and dry mouth usually occur in patients suf-
fering from a variety of autoimmune diseases, especially
in Sjøgren’s syndrome (SS). Sjøgren’s syndrome causes
substantial discomfort in mouth14,15. Several recent stu-
dies evaluated xerostomia-relieving effects of salivary
gland stimulation by low level laser therapy16, by sys-
temic pilocarpine17,18, as well as by intraoral electro-
stimulation device19. These modalities have increased
salivary output in published trials. However, pilocarpine
shows systemic side effects, whereas intraoral electro-
stimulation device and low level laser are costly and not
universally available.
Xerophthalmia occurring in SS causes ocular morbid-
ity and is a marker of disease progression. The ocular
surface status is included in most diagnostic algorithms,
either in the form of questionnaires and objective tests,
such as Schirmer test 1 and Schirmer test 2, TBUT and
surface staining with vital dye – Rose Bengal score (RBS)12.
Despite the importance of proper use of diagnostic
tests in clinical decisions, many tests have not yet been
subjected to precise evaluation to determine their clinical
utility.
There is much debate about the usefulness and exact-
ness of the Sch.1. Vitali and associates, back in 1994,
demonstrated that it is a reliable test for the diagnosis of
SS11, while other authors discussed its role20,21, showing
that Sch.1 has a moderate repeatability from visit to visit
and displays a weak correlation with subjective symp-
toms of dryness22. The most widely recognized opinion is
that Sch.1 has no significant diagnostic value in mild to
moderate dry eyes and only a very low Sch.1 score can be
regarded as a good indicator of an aqueous deficiency.
Cut off values for Sch.1 is wetting 5 mm/5 min in the
American-European Consensus Group criteria for SS4.
In our study, cut off value is far above that reference, ex-
actly 23 mm (sensitivity 75.00 and specificity 83.33).
This relatively high cut off is indicator of low sensitivity
at lower values. That kind of test cannot present clear
distinction between these two groups of patients.
If we use a common baseline test, the sensitivity
would fall to approximately 65.00; while the specificity
would have remained unchanged. Such an interpretation
of the text would significantly diminish its clinical impor-
tance and an area under the ROC curve, which was 0.781
in our study. The standard error was 0.0698 with 95%
confidence interval of 0.662–0.874 (Table 4).
According to the American-European Consensus Group
criteria, objective ocular signs are positive if any of oph-
thalmic tests (Sch.1 or RBS) showed pathological va-
lues4. It is understandable that a large number of pa-
tients in our and in other studies, are only to be diag-
nosed with SS based on the results of RBS’s, when it co-
mes to that classification category. Sch.1 than gets the
relative importance of a single test, including the impact
of disease stage and therapy on the measurement results.
However, the diagnostic value of Sch.1 is not negligible,
since the difference between the group of patients with
SS and Sicca S is statistically significant (p<0.000, Mann
Whitney U=189.00). Mean values of the test in subjects
with SS amounted to 13.81 mm, and in subjects with
Sicca S 29.17 mm.
It can be concluded that in the differential diagnosis
of SS, Sch.1 often gives false negative results, if we take
the limit value of accepted 5–15 mm/min. In our, as well
as other similar surveys, more than half of the patients
had negative values for Sch.112,20 and if the marginal test
value does not increase, its differential diagnostic value
will remain relatively weak.
Version of Schirmer test used in this study was with a
local anaesthetic application (Schirmer test 2 (Sch.2)), in
order to avoid external stimulus and show basal secre-
tion. Sch.2 showed a high sensitivity and satisfactory
specificity and, as such, a good analyticity in the differen-
tial diagnosis of a SS. Differences among the results were
statistically significant between patients with SS and
Sicca S (p<0.001, Table 2, Mann Whitney U=171.00),
suggesting the importance of simultaneous performance
of both Schirmer tests. Mean test values in group of sub-
jects with SS amounted 4.72 mm, and in the group with
Sicca S 17.17 mm. Similar to Sch.1, common marginal
values for this test are not in accordance with values ob-
tained in our study. According to current criteria, strip
wetting marginal value for the Sch.2 is 5 mm/5 min12,
whereas in our study this value reached 17 mm. With
such a value, the sensitivity of the test was 100.00 and
the specificity 66.67. If we apply the usual 5 mm, then
the sensitivity would have fallen to 68.75, with equal
specificity value, which would significantly reduce the
clinical test analyticity. Also, the area under the ROC
curve at Sch.2 is greater than at Sch.1 (0.802:0.781),
which makes it more usable and sensitive in the differen-
tial diagnosis of SS. The standard error was 0.0674, with
95% confidence interval of 0.686–0.890. However, it is im-
portant to note that there is no statistically significant dif-
ference between ROC curves of these two tests (p<0.606).
Differences found in unstimulated whole saliva (UWS)
between patients with SS and Sicca S were statistically
significant (p<0.001, Mann Whitney U=198.00), with
mean values for SS of 0.33 mL/5 min, and for the Sicca S
of 0.65 mL/5 min. Likewise, the differences in obtained
values of stimulated whole saliva (SWS) among subjects
with SS and Sicca S were significant (p<0.001, Mann
Whitney U=148.50, mean value of SS 0.88 mL/5 min, the
mean value of Sicca S 1.90 mL/5 min). From these results
it is evident that the investigated population had both
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hyposecretion components (lacrimal and salivary), and
that the differences among the groups in both cases are
significant. Such finding was also expected and it might
be assumed that the lacrimal gland biopsy would provide
histological findings (positive focus score) similar to bi-
opsy of labial salivary glands (LGB). This assumption is
based on parallel functional deficit of both exocrine glands
as well on some other similar studies23,24, which often fa-
vor the lacrimal gland biopsy over LGB.
Data from our study demonstrated that a negative
TBUT cannot exclude diagnosis of SS with great cer-
tainty (low sensitivity, 62.50). In contrast, TBUT showed
relatively high specificity (83.33), which is not in accor-
dance with other studies25.
These sensitivity and specificity values of TBUT were
shown at marginal value of 7.5 s. Most often mentioned
baseline TBUT test so far is 10 s, although in recent
years value of 8 s as a border is proposed12. Differences
between groups of subjects with SS and Sicca S was sta-
tistically significant (p<0.008), mean TBUT values in
patients with SS were pathological (8.69 s), unlike the
group with Sicca S (13.00 s).
It is obvious that these results are in line with find-
ings from other studies, although the sensitivity values
are below expectations. If the limit value TBUT rise to 10
s, the specificity of the test would fall significantly, to
50.00. Sensitivity in this case would slightly increase to
approximately 69.00, which would ultimately result in
significantly lower clinical usability of the test.
TBUT’s modest efficacy in the differential diagnosis
of SS is shown also by ROC analysis curve positioned
close above the diagonal line. Area under the ROC curve
was, compared with other objective ophthalmic tests, a
modest 0.714. The standard error was 0.0759 with 95%
confidence interval of 0.589–0.818. Results of ROC anal-
ysis in our study are congruent to results of similar
studies12.
Furthermore, in direct ROC curves comparison, TBUT
showed the minimum sensitivity for the differential diag-
nosis of SS, right below the OSDI, whose specificity is
very high (100.00). However, these differences did not
show statistically significant values as to the OSDI (p<
0.783), as when compared with Sch.1 (p<0.318) and
Sch.2 (p<0.159). In accordance with these results, a clear
distinction between these three tests, related to the clini-
cal relevance in the differential diagnosis of SS, is not
easy to distinguish, which contributes to the lack of pre-
cise research on this topic.
Rose Bengal score (RBS) proved to be the most effi-
cient objective test in ophthalmic differential diagnosis
for SS. Differences in values between the test group of
patients with SS and Sicca S were statistically highly sig-
nificant (p<0.001). The mean value in patients with SS
was 10.56, while the same in subjects with Sicca S was
2.83. The most interesting fact of the entire study was
ROC curve analysis of Rose Bengal score for a diagnosis
of SS. At ideal marginal value >6, the sensitivity and
specificity reached the ideal 100.00. This result is unique,
although similar high values are described by other re-
searchers12. ROC curve for a given variable has been
removed in the leftmost position, and the area under the
curve was ideal 1.000, standard error 0.000 with 95%
confidence interval of 0.945–1.000. ROC curve analysis
of ophthalmic tests showed the RBS as a most analytical
test. The differences found between the ROC curve of
RBS and other ophthalmologic tests were significant ac-
cording to: OSDI (p<0.001), Sch.1 (p<0.002), Sch.2 (p<
0.003) and TBUT (p <0.001).
In our, as well as in other studies26 vital staining dye
(RBS), has the highest value of the likelihood ratio, clas-
sifying it as a test of choice for SS diagnosis. Different re-
sults may be consequently to the lack of sufficient data
for the test in some trials, which were performed only at
fluorescein negative corneas, which would show a rela-
tively flat curve ROC analysis12.
In most studies, including American-European Con-
sensus Group criteria, the item for ocular subjective
symptoms only includes few simple questions concerning
the common feeling of sandy eyes, eye discomfort, and
use of tear substitutes. Using similar questionnaires re-
lated to sicca symptoms, previously known as the method
that should be regularly used in clinical practice if there
is suspicion of tear film dysfunction27. The total score re-
sponses to ophthalmologic symptoms, in the sense of dis-
comfort due to dry eye, based on multiple queries, effec-
tively distinguishes the group of patients with SS from
patients with Sicca S28. In our study the differences be-
tween the additive values of tests were statistically sig-
nificant between subjects with SS and Sicca S (p<0.003,
Mann Whitney U=225.00). Mean value in the group of
subjects with SS was 52.66, and in subjects with Sicca S
34.75.
Cut off value determined by ROC analysis of the test
was >55.6. At the same, OSDI has a sensitivity of 56.25
and specificity of 100.00. In ROC curves analysis of stud-
ied ophthalmic tests, OSDI occupies the penultimate po-
sition, before TBUT, with the area under the ROC curve
of 0.740, standard error of 0.0632 and 95% confidence in-
terval between 0.617 and 0.840. Difference between ROC
curves of OSDI and RBS is statistically significant (p<
0.001). Compared with results of other ROC analysis, no
statistically significant differences were found (compared
with: Sch.1 p<0.597, Sch.2 p<0.453 and TBUT p<0.783).
In conclusion we can say that the OSDI question-
naire, which we used in our research10, showed high
specificity and relatively acceptable diagnostic features,
indicating that the OSDI score has a certain role in clini-
cian’s orientation towards the SS diagnosis. However,
this level of reliability proved to be significantly lower
than the results of similar studies27,28.
Biopsy of small salivary as one of the most analytical
tests in the differential diagnosis of SS4, confirmed the
high clinical usefulness in our study. ROC analysis estab-
lished very high analytical value of test, with an area un-
der the ROC curve of 0.823, standard error of 0.0646 and
95% confidence interval of 0.709–0.906.
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Depending on the attitudes of individual researchers,
a biopsy is indicated if there is suspicion on final diagno-
sis based on clinical symptoms. However, it is important
to note that the biopsy has a broader clinical utility, be-
cause it can detect other diseases, such as the sarcoidosis.
In the positive biopsy findings at Chisholm-Mason
grading system29 the sensitivity of the test was 56.25,
specificity 100.00. Biopsy showed a very good, but not the
best, usability in the differential diagnosis of SS. The rea-
sons for this result may be different. One of them is cer-
tainly the way of tissue collection in which focal aggrega-
tion of lymphocytes is detected and quantified, which in
our case consisted of a single section. Described »multi-
level« sections30, where results are presented as mean
value of three different sections, distant at least 200 mi-
crons, in order to avoid the section of the same focus31,
could lead to an increase of the existing diagnostic value
of accessory salivary glands biopsy.
Conclusion
Ophthalmic tests provide high quality clinical orien-
tation and sometimes even the answer to the question of
whether the patient has Sjøgren’s syndrome or Sicca
syndrome. In the absence of quality research in this area
of medicine, this approach greatly contributes to the
rapid diagnosis and orientation, if the tests are properly
used and if it is known what each of them represents. Re-
sults from the present study show the usefulness and ef-
ficiency of implementation of the data obtained from the
subjective and objective ophthalmic testing in the diag-
nostic criteria for SS. The results confirm the relatively
poor reliability of Sch.1, OSDI and TBUT in the differen-
tial diagnosis of a SS. In contrast, same results show the
test with vital color staining (RBS) as a test of choice in
the differential diagnosis of a SS. Biopsy of the labial sali-
vary glands is still considered the gold standard in diag-
nosis of SS and has wide clinical utility, but it is invasive
and may be unpleasant method. RBS should, as non-in-
vasive and simple test, with very high specificity and sen-
sitivity (superior to biopsy), be performed before biopsy,
as it can accurately indicate a need for further invasive
investigations. We suggest making an ophthalmological
tests algorithm that could distinguish patients with SS
and those with Sicca syndrome without SS. Such an algo-
rithm should contain test of vital staining color (RBS) as
the most reliable ophthalmic test.
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DIFERENCIJALNO DIJAGNOSTI^KA U^INKOVITOST ROSE BENGAL SCORE TESTA U
PACIJENATA SA SJÖGRENOVIM SINDROMOM
S A @ E T A K
Cilj istra`ivanja bio je procijeniti klini~ku vrijednost Rose Bengal testa pri diferencijalnoj dijagnozi Sjøgrenovog
sindroma (SS), te napraviti usporedbu s ostalim provedenim oftalmolo{kim i salivarnim testovima. Svim sudionicima
u~injeno je: mjerenje nestimulirane (UWS) i stimulirane salivacije (SWS), biopsija `lijezda slinovnica (LGB ili focus
score), oftalmolo{ki upitnik (OSDI) i objektivni testovi: Schirmer test 1 (Sch.1), Schirmer test 2 (Sch.2), Tear Break-up
Time (TBUT) test i Rose Bengal test (RBS). Podaci su analizirani pomo}u Mann Whitney U-testa, ROC analize, uz
izra~unane specifi~nosti i osjetljivosti, i Spearmanovog testa korelacije. ROC krivulje pokazale su slabije dijagnosti~ke
vrijednosti za TBUT i OSDI. Rezultati ROC analize za Sch.1, Sch.2 i LGB prikazali su dobra dijagnosti~ka svojstva, dok
je RBS imao idealne parametre (osjetljivost 100,00, specifi~nost 100,00, AUC 1000) u provedenom ispitivanju. Studija
otkriva slabu pouzdanost TBUT-a, OSDI-a i Sch.1, te isti~e RBS kao test izbora u diferencijalnoj dijagnostici SS.
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